Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can affect multiple parts of the body. In 2025, it was estimated that around 512,000 individuals in the United States were living with SLE, as per DelveInsight analysis, with new treatments for SLE urgently needed as 40% of treated SLE patients relapse on first-line drugs for SLE. The prevalence is significantly higher in females, who account for over 90% of all cases. Currently, FDA-approved SLE treatment drugs include only belimumab (BENLYSTA) and anifrolumab (SAPHNELO), while rituximab remains off-label. The SLE drug development pipeline features promising SLE drugs in Phase III, including li...
